- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Breaking Down Taletrectinib’s FDA Approval: Jorge J. Nieva, MD
In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, and taletrectinib’s potential to redefine first-line therapy.
Taletrectinib (Ibtrozi; Nuvation Bio Inc) was approved by the FDA on June 11 to treat ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), based on results from the TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials.1 These single-arm, multinational studies evaluated taletrectinib in both tyrosine kinase inhibitor (TKI)-naïve and TKI-pretreated patients, assessing its efficacy in first-line and resistant settings.2,3
Notably, taletrectinib demonstrated a 90% response rate in TKI-naïve patients in TRUST-I and 85% in TRUST-II, marking a significant improvement over existing therapies like crizotinib (Xalkori; Pfizer) and entrectinib (Rozlytrek; Genentech). The corresponding durations of response at 12 months or more were 72% and 63%.4
Although cross-trial comparisons require caution, these high response rates position taletrectinib as a potential first-line standard, marking a novel approach for this subtype of NSCLC and its rare ROS1 mutation. In particular, taletrectinib has a favorable toxicity profile, with lower risk of central nervous system (CNS) toxicity compared with other therapeutics, although with a slightly higher rate of gastrointestinal (GI) effects. For clinicians, this balance may make it a preferred choice, as managing GI toxicity can be easier than CNS adverse effects.
Despite its advantages, access may vary globally, with crizotinib remaining the only option in some regions. However, in the US, taletrectinib is expected to join entrectinib and repotrectinib as a leading TKI for ROS1-positive NSCLC, offering personalized treatment based on toxicity tolerance. Its approval marks progress in targeting ROS1 resistance and improving outcomes for this subset of patients living with lung cancer.
In this interview with TRUST-I and TRUST-II investigator, Jorge J. Nieva, MD, associate professor of clinical medicine, Keck School of Medicine, and section head of thoracic and head and neck tumors, University of Southern California, he walks us through the design of the trials, the results that supported the FDA approval, and taletrectinib’s potential to redefine first-line therapy.
References
- FDA approves taletrectinib for ROS1-positive non-small cell lung cancer. News release. FDA. June 11, 2025. Accessed June 20, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
- A study of AB-106 in subjects with advanced NSCLC harboring ROS1 fusion gene. ClinicalTrials.gov. Updated October 30, 2023. Accessed June 20, 2025. https://clinicaltrials.gov/study/NCT04395677
- Taletrectinib phase 2 global study in ROS1 positive NSCLC (TRUST-II). ClinicalTrials.gov. Updated November 21, 2024. Accessed June 20, 2025. https://clinicaltrials.gov/study/NCT04919811
- Shaw M. Taletrectinib approved for ROS1-positive NSCLC. AJMC®. June 11, 2025. Accessed June 20, 2025. https://www.ajmc.com/view/taletrectinib-approved-for-ros1-positive-nsclc
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
June 23rd 2025The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
June 20th 2025Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.
Read More
